^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P2.14-02 - TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
Published date:
07/12/2022
Excerpt:
Mutations in TP53 gene were detected in 11 (52.3%) patients...In contrast, in ROS1+/TP53- patients, RR was 50%, median PFS was 26.3 months (HR: 2.30, 95% CI: 0.78-6.75) and median OS was 30.7 months (HR: 2.75, 95% CI: 0.84-8.96).
